CY2200152T2 - Καθαρισμος εμβολιων συζευγματος πολυσακχαριτη-πρωτεϊνης μεσω υπερδιηθησης με διαλυματα θειϊκου αμμωνιου - Google Patents

Καθαρισμος εμβολιων συζευγματος πολυσακχαριτη-πρωτεϊνης μεσω υπερδιηθησης με διαλυματα θειϊκου αμμωνιου

Info

Publication number
CY2200152T2
CY2200152T2 CY20072200004T CY072200004T CY2200152T2 CY 2200152 T2 CY2200152 T2 CY 2200152T2 CY 20072200004 T CY20072200004 T CY 20072200004T CY 072200004 T CY072200004 T CY 072200004T CY 2200152 T2 CY2200152 T2 CY 2200152T2
Authority
CY
Cyprus
Prior art keywords
ultrafilteration
polysaccharide
purification
ammonium sulphate
protein conjugate
Prior art date
Application number
CY20072200004T
Other languages
English (en)
Original Assignee
Connaught Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Laboratories filed Critical Connaught Laboratories
Publication of CY2200152T2 publication Critical patent/CY2200152T2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CY20072200004T 1998-12-29 2007-08-23 Καθαρισμος εμβολιων συζευγματος πολυσακχαριτη-πρωτεϊνης μεσω υπερδιηθησης με διαλυματα θειϊκου αμμωνιου CY2200152T2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/221,728 US6146902A (en) 1998-12-29 1998-12-29 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP99967388A EP1140156B1 (en) 1998-12-29 1999-12-16 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions

Publications (1)

Publication Number Publication Date
CY2200152T2 true CY2200152T2 (el) 2010-07-28

Family

ID=22829099

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20071100130T CY1105985T1 (el) 1998-12-29 2007-01-31 Καθαρισμος εμβολιων συζευγματος πολυσακχαριτη- πρωτεϊνης μεσω υπepδιηθησης με διαλυματα θειϊκου αμμωνιου
CY20072200004T CY2200152T2 (el) 1998-12-29 2007-08-23 Καθαρισμος εμβολιων συζευγματος πολυσακχαριτη-πρωτεϊνης μεσω υπερδιηθησης με διαλυματα θειϊκου αμμωνιου
CY20111100357T CY1111375T1 (el) 1998-12-29 2011-04-05 Καθαρισμος εμβολιων συζευγματος πολυσακχαριτη-πρωτεϊνης μεσω υπερδιηθησης με διαλυματα θειϊκου αμμωνιου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071100130T CY1105985T1 (el) 1998-12-29 2007-01-31 Καθαρισμος εμβολιων συζευγματος πολυσακχαριτη- πρωτεϊνης μεσω υπepδιηθησης με διαλυματα θειϊκου αμμωνιου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100357T CY1111375T1 (el) 1998-12-29 2011-04-05 Καθαρισμος εμβολιων συζευγματος πολυσακχαριτη-πρωτεϊνης μεσω υπερδιηθησης με διαλυματα θειϊκου αμμωνιου

Country Status (12)

Country Link
US (1) US6146902A (el)
EP (3) EP2292261A1 (el)
AT (2) ATE347906T1 (el)
AU (1) AU2367500A (el)
CA (2) CA2358022C (el)
CY (3) CY1105985T1 (el)
DE (3) DE69943169D1 (el)
DK (2) DK1762245T3 (el)
ES (2) ES2277462T3 (el)
HK (1) HK1106999A1 (el)
PT (2) PT1762245E (el)
WO (1) WO2000038711A2 (el)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
CA2783274C (en) * 2000-06-29 2018-08-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition with reduced dose of haemophilus influenza type b
EP1334349B1 (en) * 2000-10-18 2012-03-07 Art & Science, Inc. Method for diluting a fluid and detecting analytes within a diluted fluid
JP2005504718A (ja) 2001-01-23 2005-02-17 アヴェンティス パストゥール 多価髄膜炎菌多糖−タンパク質複合ワクチン
PT2280065T (pt) 2001-04-04 2021-02-16 Dsm Ip Assets Bv Lactase purificada
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
CN1819843A (zh) 2003-05-07 2006-08-16 安万特巴斯德公司 增强脑膜炎球菌疫苗接种免疫原性的方法
BRPI0410341B8 (pt) 2003-05-07 2021-05-25 Sanofi Pasteur Inc conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
BRPI0411815A (pt) * 2003-06-23 2006-08-08 Baxter Int vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
AU2004251742A1 (en) 2003-06-23 2005-01-06 Sanofi Pasteur, Inc. Immunization method against Neisseria meningitidis serogroups A and C
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US20050169941A1 (en) * 2004-01-29 2005-08-04 Andrew Lees Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
CN101048177A (zh) * 2004-08-30 2007-10-03 圣诺菲·帕斯图尔公司 多价的脑膜炎球菌产生的多糖－蛋白质偶联物和疫苗
WO2006034320A2 (en) * 2004-09-21 2006-03-30 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
MX2007016403A (es) * 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
GB0513852D0 (en) * 2005-07-06 2005-08-10 Celltech R&D Ltd Biological products
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
MX2009010221A (es) 2007-03-23 2009-10-19 Wyeth Corp Proceso abreviado de purificacion para la produccion de polisacaridos capsulares de streptococcus pneumoniae.
TW200914042A (en) 2007-05-02 2009-04-01 Glaxosmithkline Biolog Sa Vaccine
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CA2777837C (en) 2008-10-27 2017-07-11 Novartis Ag Purification method
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
RU2524436C2 (ru) 2008-12-18 2014-07-27 УАЙТ ЭлЭлСи Способ получения жидкой фракции, содержащей изолированные высокомолекулярные капсульные полисахариды streptococcus pneumoniae, и жидкая фракция, полученная таким способом
CN102257155B (zh) * 2008-12-18 2016-03-02 惠氏有限责任公司 控制肺炎链球菌血清型19a多糖分子量的方法
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
US8974799B2 (en) 2009-09-30 2015-03-10 Novartis Ag Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
DK2493498T3 (en) 2009-10-30 2017-05-08 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 and type 8 capsule saccharides
US8105843B2 (en) * 2009-11-04 2012-01-31 Buchanan Thomas M Methods and devices to enhance sensitivity and evaluate sample adequacy and reagent reactivity in rapid lateral flow immunoassays
CA2836140C (en) 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
AU2010351576B2 (en) 2010-04-23 2014-08-14 FinaBioSolutions, LLC Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
TR201909110T4 (tr) 2011-09-14 2019-07-22 Glaxosmithkline Biologicals Sa Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
CA2885625A1 (en) 2012-10-02 2014-04-10 Glaxosmithkline Biologicals S.A. Nonlinear saccharide conjugates
AR092897A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN104387491B (zh) * 2014-11-25 2017-12-05 中国医学科学院医学生物学研究所 一种b型流感嗜血杆菌荚膜多糖的制备方法
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
EP3518968B1 (en) 2016-10-03 2022-01-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
EP3576759A4 (en) 2017-01-31 2020-11-11 Merck Sharp & Dohme Corp. PROCESS FOR THE PREPARATION OF CAPSULE POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19F
AU2018328037B2 (en) 2017-09-07 2024-03-07 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
SG11202005255PA (en) 2017-12-06 2020-07-29 Merck Sharp & Dohme Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
KR20210005158A (ko) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
WO2020061564A1 (en) 2018-09-23 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
TWI788610B (zh) 2018-12-19 2023-01-01 美商默沙東有限責任公司 包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法
US20220211859A1 (en) 2019-05-10 2022-07-07 Glaxosmithkline Biologicals Sa Conjugate production
JP2023529925A (ja) 2020-06-12 2023-07-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ナノ粒子ワクチンを使用する細菌免疫化
US20240000958A1 (en) 2020-11-13 2024-01-04 Glaxosmithkline Biologicals Sa Novel carriers and conjugation methods
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
US20240101597A1 (en) * 2021-02-26 2024-03-28 The Penn State Research Foundation Separation apparatus and method
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
WO2023200704A1 (en) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Protein-saccharide conjugation with sodium cyanoborohydride

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4456691A (en) * 1983-02-28 1984-06-26 Suad Stark Antigen for PCB, antibody raised by same, and method of making same
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4780409A (en) * 1985-05-02 1988-10-25 Genetic Systems Corporation Thermally induced phase separation immunoassay
JPH0643336B2 (ja) * 1988-06-30 1994-06-08 呉羽化学工業株式会社 血管増殖抑制剤
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
AU1140495A (en) * 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules

Also Published As

Publication number Publication date
CA2358022A1 (en) 2000-07-06
DK1762245T3 (da) 2011-04-04
EP1762245A3 (en) 2007-04-25
EP1762245A2 (en) 2007-03-14
DK1140156T3 (da) 2007-03-26
ATE347906T1 (de) 2007-01-15
DE69934434D1 (de) 2007-01-25
DE06025470T1 (de) 2007-08-02
HK1106999A1 (en) 2008-03-28
CY1105985T1 (el) 2011-04-06
DE69934434T2 (de) 2008-01-03
ATE496633T1 (de) 2011-02-15
PT1762245E (pt) 2011-05-02
AU2367500A (en) 2000-07-31
ES2278551T1 (es) 2007-08-16
EP1140156B1 (en) 2006-12-13
CA2358022C (en) 2008-03-11
CY1111375T1 (el) 2015-08-05
EP2292261A1 (en) 2011-03-09
EP1762245B1 (en) 2011-01-26
PT1140156E (pt) 2007-02-28
ES2278551T3 (es) 2011-04-11
CA2621097A1 (en) 2000-07-06
EP1140156A2 (en) 2001-10-10
WO2000038711A2 (en) 2000-07-06
WO2000038711A3 (en) 2000-10-19
US6146902A (en) 2000-11-14
ES2277462T3 (es) 2007-07-01
DE69943169D1 (de) 2011-03-10

Similar Documents

Publication Publication Date Title
CY2200152T2 (el) Καθαρισμος εμβολιων συζευγματος πολυσακχαριτη-πρωτεϊνης μεσω υπερδιηθησης με διαλυματα θειϊκου αμμωνιου
PT1163237E (pt) Derivados de amida
DE69829588D1 (de) Farblose wässrige Ammoniumsulfidlösung
ATE284389T1 (de) Zyklische n-acylamin-derivate
DE60043343D1 (de) Chromenderivate
FR07C0051I2 (fr) Dérivés de l' Erythropoietine
TR199501209A2 (tr) Urea türevleri
DE69939133D1 (de) Objekt-Hashing mit schrittweisen Änderungen
FR2741001B1 (fr) Pince utilitaire
DE69934299D1 (de) Gruppe b-streptococcus antigene
EE200100131A (et) Süstelahuste parem stabiilsus
DE60017804D1 (de) Verschlussklammer
DK1070077T3 (da) 15-Leddede ketolid-lactamer med antibakteriel virkning
DE50101049D1 (de) Ammoniumgruppen aufweisende organosiliciumverbindungen
DE69914279D1 (de) Klammer
DE59914136D1 (de) Dübel
ID25867A (id) Pembuatan poliamida dengan cara destilasi reaktif
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
DE69902171D1 (de) Wellenleiter-endfläche
DE69925752D1 (de) Wässrige haarverformungsmittel
DE69935796D1 (de) Verschlussklammer
DK1102746T3 (da) Substituerede phenylamidiner med antitrombotisk virkning
FI980856A0 (fi) Andningsskydd utrustad med en identifierare
DE50001982D1 (de) Substituierte phenylcyclohexancarbonsäureamide mit adenosinaufnahme-hemmender wirkung
ID26109A (id) Pembuatan garam-garam hidroksilammonium